Dingzhi Huang

21PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 23, 2026
Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non-small-cell lung cancer: a randomized, multicenter, phase II trial.

|Oct 24, 2025
Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway.

Wenting Liu, Ting Mei, Yantao Jiang

|Feb 28, 2025
ACT001 Suppresses the Malignant Progression of Small-Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti-Tumor Immunity.

Xiao-Jing Ding, Ting Mei, Xiao-Nan Xi

|Jan 31, 2025
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.

Tingting Qin, Jingya Wang, Jian Wang

|Jan 06, 2025
Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial.

Shun Lu, Ying Cheng, Dingzhi Huang

|Aug 07, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Qiaofeng Zhong, Longfeng Zhang, Lin Wu

Pageof 4

Frequent Collaborators

4 joint publications

Jun Zhao

3 joint publications

Chengbo Han

3 joint publications

Song Xu

3 joint publications

Shun Lu